Bayer ordered to pay $81M in Roundup cancer case
A federal jury has ordered Bayer to pay $81 million to a California man who said his use of the company's Roundup weedkiller caused him to develop cancer. The ruling is the latest against Bayer involving Roundup, which was developed by St. Louis-based Monsanto before the company was acquired by Bayer last year for $62.5 billion. A San Francisco jury said Wednesday that the company is liable for the man's non-Hodgkin lymphoma, according to Reuters. Edwin Hardeman was awarded $5.9 million in compensatory…
Lymphomas are the heterogeneous group of malignant diseases characterized by proliferation of malignant lymphoid cells or their precursors. Lymphomas are the ninth most common cancer worldwide and constitute 3.2% of malignant tumor. Lymphomas are generally classified to two main categories: Hodgkin's lymphomas (HL) and the non-Hodgkin lymphomas (NHL), and about 90% are NHL. Non-Hodgkin lymphoma represents 4.3% of all new cancer cases in the U.S. and the ninth most common cancer in male patient of Taiwan.
Danny Feltwell Jr, 10, suffered from non-Hodgkin lymphoma. A bone marrow transplant treated his relapse, but then he got graft-versus-host disease. An experimental treatment has him back to pitching.
A gardener in Australia has sued Bayer over its Monsanto Roundup weedkiller, the first such lawsuit against the German pharmaceutical giant in that country. Michael Ogalirolo, 54, a self-employed gardener from Melbourne, said he was diagnosed with non-Hodgkin lymphoma, a type of leukemia, after using Monsanto’s Roundup for more than 20 years, Reuters reported. “We have great sympathy for any individual with cancer, but the extensive body of scie nce on glyphosate-based herbicides over four…
Varrie Dunlop, 26, of Ringwood, Hampshire, was diagnosed with stage four non-Hodgkin's lymphoma last November after doctors initially dismissed her fatigue as a viral infection.
Targeting IL-6 receptor reduces IgM levels and tumor growth in Waldenström macroglobulinemia. Oncotarget. 2019 May 21;10(36):3400-3407 Authors: Han W, Matissek SJ, Jackson DA, Sklavanitis B, Elsawa SF Abstract The tumor microenvironment (TME) plays an important role in cancer cell biology and is implicated in resistance to therapy. In Waldenström macroglobulinemia (WM), a subtype of Non-Hodgkin lymphoma, the TME modulates WM biology by secreting cytokines that promote the malignant phenotype. In previous work, we have shown that TME-IL-6 promotes WM cell growth and IgM secretion in WM. Tocili...
Conclusion: We report for the first time a case of a patient with Muir-Torre syndrome who developed an orbital recurrent SC with an incidental finding of a lacrimal gland B non-Hodgkin lymphoma consistent with SLL. Clinicians should be aware of the possibility of this coexistence of multiple cancer types in patients with sebaceous carcinoma and Muir-Torre syndrome.Ocul Oncol Pathol
PHILADELPHIA - A husband and wife on May 30 sued Monsanto Co. in federal court in Pennsylvania, contending that the wife developed non-Hodgkin lymphoma (NHL) as a result of exposure to the company's herbicide Roundup, which the plaintiffs say was marketed despite the company's knowledge that it causes cancer (Ruth Yobs, et al. v. Monsanto Co., No. 19-2362, E.D. Pa.).
(American Society of Hematology) How slow -- or fast -- older individuals with blood cancers are able to walk four meters (about 13 feet) holds critical information about their overall health and strongly predicts survival and unplanned hospital visits regardless of age, cancer or treatment type, or other factors, according to a new study published today inBlood. The association was strongest in those with non-Hodgkin lymphoma.
ConclusionsIn the setting of a literature reporting mainly null and some positive associations, and the lack of a clear methodologic explanation for our inverse association restricted to NHW men, the current body of evidence suggests that there is no association of blood transfusion with risk of NHL.
Conclusion: Development of a fragmented QRS pattern in response to cancer therapy emerges as a new parameter potentially predictive of chemotherapy-induced cardiotoxicity.Oncol Res Treat